Myeloproliferative Neoplasms: Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Polycythemia vera, essential thrombocythemia and primary myelofibrosis are currently classified as myeloproliferative neoplasms and represent a stem cell-derived clonal myeloproliferation. Current diagnosis is made according to the 2008 World Health Organization classification system that utilizes both bone marrow histology and molecular markers. Recent information has revealed the presence of JAK2 and MPL mutations in the majority of patients with these disorders. Accordingly, the therapeutic value of anti-JAK2 drugs is currently being investigated.

Original languageEnglish (US)
Title of host publicationPractical Hemostasis and Thrombosis
Subtitle of host publicationSecond Edition
PublisherWiley-Blackwell
Pages147-156
Number of pages10
ISBN (Print)9781405184601
DOIs
StatePublished - May 5 2010

Keywords

  • Classification
  • Diagnosis
  • JAK2
  • MPL
  • Polycythemia
  • Prognosis
  • Thrombocythemia. Myelofibrosis
  • Treatment
  • V617F

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Myeloproliferative Neoplasms: Essential Thrombocythemia, Polycythemia Vera, and Primary Myelofibrosis'. Together they form a unique fingerprint.

  • Cite this